|
|
| | GZD 824 Basic information |
| Product Name: | GZD 824 | | Synonyms: | 4-Methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide;3-(2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;GZD8824;GZD824;GZD-824;GZD 824;GZD-824 Free;GZD 824;GZD824;GZD-824 | | CAS: | 1257628-77-5 | | MF: | C29H27F3N6O | | MW: | 532.56 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1257628-77-5.mol |  |
| | GZD 824 Chemical Properties |
| Boiling point | 630.4±55.0 °C(Predicted) | | density | 1.39±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 100 mg/mL (187.77 mM) | | form | A crystalline solid | | pka | 9.04±0.40(Predicted) |
| | GZD 824 Usage And Synthesis |
| Description | GZD-824 is an orally available inhibitor of a broad spectrum of Bcr/Abl tyrosine kinase mutants including T315I (IC50s = 0.34 and 0.68 nM for wild-type Bcr/Abl and Bcr/AblT315I, respectively). It has been shown to suppress the proliferation of Bcr/Abl-positive K562 and Ku812 human chronic myelogenous leukemia cells (IC50s = 0.2 and 0.13 nM, respectively) and induce tumor regression in mouse xenograft tumor models driven by either wild-type or mutant Bcr/Abl. | | Uses | GZD824 is a orally bioavailable inhibitor that targets phosphorylated and non-phosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) kinases. It is a COVID19-related research product. |
| | GZD 824 Preparation Products And Raw materials |
|